---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-24-000009"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:26:59.803526+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Xencor posts Phase 2 data for vudalimab (PD1 x CTLA-4) in mCRPC

## Summary
- Additional clinical data from Phase 2 study of vudalimab monotherapy in metastatic castration-resistant prostate cancer posted on website.
- Presentation includes vudalimab, a bispecific PD1 x CTLA-4 antibody, corporate overview.
- No specific efficacy/safety figures provided in the filing; refer to full presentation.

## SEC filing metadata
- accession: 0001326732-24-000009
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673224000009/0001326732-24-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673224000009/xncr-20240306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-24-000009
- JSON: https://secwatch.observer/filing/0001326732-24-000009.json
- Plain text: https://secwatch.observer/filing/0001326732-24-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.